{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1116.222",
  "meta": {
    "versionId": "9",
    "lastUpdated": "2021-03-06T01:00:18.000-05:00"
  },
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.222",
  "version": "20210306",
  "name": "Aprepitant Oral",
  "status": "active",
  "date": "2021-03-06T01:00:18-05:00",
  "publisher": "American Society of Clinical Oncology Steward",
  "compose": {
    "include": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05022022",
        "concept": [
          {
            "code": "1729308",
            "display": "aprepitant 125 MG Powder for Oral Suspension"
          },
          {
            "code": "403810",
            "display": "aprepitant 80 MG Oral Capsule"
          },
          {
            "code": "403811",
            "display": "aprepitant 125 MG Oral Capsule"
          },
          {
            "code": "644088",
            "display": "aprepitant 40 MG Oral Capsule"
          },
          {
            "code": "754508",
            "display": "{1 (aprepitant 125 MG Oral Capsule) / 2 (aprepitant 80 MG Oral Capsule) } Pack"
          }
        ]
      }
    ]
  }
}